Skip to content

Lexicon Pharmaceuticals

US · LXRX #3430 by market cap
1.53 -0.14 -8.38%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 1.66 -0.60%
After-hours 1.50 -1.80%
2.641.421.532026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on LXRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -7.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 99.4% Better than 99%
Operating margin -98.2% Better than 7%
Net margin -101.1% Better than 7%
Return on equity -39.7% Better than 11%
Return on invested capital -23.0% Better than 12%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -33.5% Better than 15%
6-month return -29.2% Better than 19%
12-month return (ex latest month) 11.2% Better than 47%
Distance below 52-week high 42.9% Better than 25%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.9x Better than 85%
Debt to assets 34.0% Better than 35%
Interest coverage -5.0x Better than 17%
Free cash flow / net income 87.4% Better than 30%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 282.4% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -14.53%
1M -3.16%
3M -29.82%
6M -30.77%
YTD +33.04%
1Y +15.91%
3Y +29.66%
5Y -69.15%

Key statistics

Price & volume

Prev close
1.67
Open
1.66
Day range
1.47 - 1.70
Avg price
1.57
Volume
4.21M
Turnover
6.62M
Amplitude
13.75%
52-week range
1.10 - 2.68

Valuation

P/E
-10.93
P/E (TTM)
-10.20
P/B
4.16
EPS
-0.14
Net profit
-62.33M
Net assets
163.85M

Share structure

Market cap
681.21M
Float cap
335.43M
Shares out
445.23M
Float shares
219.24M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 27% of range
1.10 2.68

42.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.45M net over the window

Short interest

Shares short
25.88M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Lexicon Pharmaceuticals (LXRX)?

Lexicon Pharmaceuticals last traded at 1.53. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Lexicon Pharmaceuticals's market cap?

About 681.21M.

What is the P/E ratio of Lexicon Pharmaceuticals?

The trailing twelve-month P/E is -10.20. The Valuation tab shows it against the stock's own five-year range.

Does Lexicon Pharmaceuticals pay a dividend?

Lexicon Pharmaceuticals does not currently pay a regular dividend.

Is Lexicon Pharmaceuticals a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 5.85, which implies 282.4% upside from the current price. This is not investment advice.

What is Lexicon Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Lexicon Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.

Lexicon Pharmaceuticals discussion 0 comments

Add a comment